戦戦 Chapter 3 Business Strategy Business Strategy For Sustainable Growth This section looks at the business environment faced by Astellas, as well  as the business model and strategic priorities that we are targeting to  realize sustainable growth over the medium to long term. Astellas pursues a Global Category Leader (GCL) business  model, focusing resources on the creation of innovative  pharmaceuticals based on its excellent R&D capabilities.  Under the GCL business model, our aim is to establish a  competitive edge as a leader in multiple highly specialized  therapeutic areas with a high level of unmet medical  need, and to supply high-value-added pharmaceuticals  worldwide. In this way, we are targeting the sustainable  enhancement of enterprise value by contributing to better  health for people around the world. We have established GCL status for Astellas in the  areas of urology and transplantation, two categories  where we are globally competitive. We are currently build- ing up our business platform to develop oncology as a  third GCL area. Under the 2014 Mid-Term Management Plan covering the  five-year period from fiscal 2010 to fiscal 2014, we are  pursuing three types of growth strategies; a therapeutic  area strategy, a regional strategy and an R&D innovation  strategy—underpinned by a focus on efficient operations. 2014 Mid-Term Management Plan Business Model Business Model & Mid-Term Management Plan Three Growth Strategies under the 2014 Mid-Term Management plan Astellas Pharma Inc.  _ Annual Report 2014 22 Therapeutic Area Strategy Regional Strategy - Maintain and strengthen GCL position in urology and transplantation - Swiftly establish a business base in oncology to realize a third GCL goal R&D Innovation  Strategy - Promote Precision Medicine drug discovery approach based on molecular targeting and precision diagnostics - Concentrate management resources on focus therapeutic areas (urology, immunology (including  transplantation) & infectious diseases, oncology, neuroscience and DM complications & kidney diseases) - Utilize cutting-edge technologies (e.g. antibody pharmaceuticals) and take initiatives in new areas and drug  discovery platform technologies (vaccines and regenerative medicine) - Leverage global development framework to bolster drug development pipelines - Achieve a well-balanced four-region business base covering Japan, Americas, EMEA and Asia & Oceania (expand growth products and launch new products in each region) - Invest further in emerging countries 